NANOG and cancer: TF binding sites (Fig. 2C; Supplementary Data 2) and IPA analyses (Supplementary Table 3; Supplementary Fig. 4F) showed that hiPSC-specific enhancers and SEs regulate pluripotency genes (NANOG, POU5F1, MYC)100 and TFs involved in the cell cycle (E2F1, MYBL2)101,102, non-neural tissue specification (MYOCD; GATA4)103,104, DNA damage response (NER, BER, ATM signalling), and tissue-specific cancer.